What Bioregulator Peptides Are

Search for bioregulator peptides and you hit a vocabulary nobody defines: cytomax, cytogen, Khavinson, epitalon, Thymalin, Cortexin. Behind all of it is one idea and one body of research, most of it produced by a single Russian institute over roughly forty years. The products split into two families that are not interchangeable, and the evidence base behind both is unlike anything else in peptide research.

The one idea the whole class rests on

Bioregulator peptides are very short chains, usually two to four amino acids. The claim their developers make is not that they behave like a drug at a surface receptor, but that they are tissue-specific signals: a liver peptide talks to liver cells, a pineal peptide to pineal cells. The proposed mechanism is that peptides this small reach the cell nucleus, interact with histones and DNA, and recognise sequences inside gene promoters, changing which genes are switched on. A 2001 report from the same group described four synthetic peptides, each stimulating growth in the rat tissue explant it was matched to. That is the tissue-specificity idea at its most concrete. It is also a mechanism finding rather than an outcome, and the two get run together constantly in what gets written about the class.^{[1, 2]}

Where the class came from

The work traces to two Soviet researchers, Vyacheslav Morozov and Vladimir Khavinson. In 1985 they published on what they called cytomedins, peptide fractions isolated from animal organs, and argued those fractions regulated genetic activity. Two years later they laid out the clinical programme in Voenno-meditsinskii Zhurnal, the Soviet military medical journal. The research later settled at the St Petersburg Institute of Bioregulation and Gerontology, the affiliation printed on most of the papers a reader will find. Khavinson's name appears on so much of this literature that it doubles as a class label: a seller who says Khavinson peptides means the same products as bioregulators.^{[3, 4, 5]}

Cytomax and cytogen: what the labels actually mean

The class splits in two, and that split matters more than any marketing copy written about it. The first family is the organ extracts, peptide fractions prepared from animal tissue and sold under names like Thymalin (thymus), Epithalamin (pineal) and Cortexin (brain cortex). The published literature calls these cytomedins. Cytomax is a retail product-line label for the same family, not a term the indexed research uses. The second family is synthetic: short defined peptides made by copying a sequence found in the extracts. The literature calls these cytogens and names them outright, including Cortagen, Epithalon, Livagen and Vilon. Epitalon and Pinealon both belong to that second family, and our data sheets at /peptides/epitalon and /peptides/pinealon cover what is known about each.^{[2, 6]}

Why the difference between the two families matters

Standardisation. An extract is a mixture whose exact composition depends on the batch, the source animal and the extraction method; a synthetic tripeptide is one molecule anyone can specify and verify against a certificate of analysis. Research on the two families is therefore not interchangeable, even when a storefront lists them side by side as if they were grades of the same product. A lifespan result obtained with a pineal extract says nothing certain about a three-amino-acid peptide modelled on it, and the literature routinely runs the two together.

What the research actually measured

Most of what exists is animal and cell work. In a 1989 study, mice given monthly pineal-factor polypeptides lived on average 20 per cent longer when the course began young and 17 per cent longer when it began in middle age, while thymus factor extended lifespan only in the younger animals. In fruit flies, epitalon raised mean lifespan by 11 to 16 per cent. And in 2003 the same group reported that Epithalon switched on telomerase and lengthened telomeres in cultured human fetal fibroblasts, cells that normally carry no telomerase at all.^{[7, 8, 9]}

The human claim, and how big it is

A 2003 paper describes 266 elderly people followed for six to eight years, given Thymalin, Epithalamin, both, or neither. The authors report mortality 1.6 to 2.5-fold lower in the peptide groups, and 4.1-fold lower in a subgroup that received both preparations every year for six years. Those are extraordinary figures for any intervention in older adults, and they carry most of the retail case for bioregulators. They are also the claim with the least outside corroboration behind them.^[10]

The replication problem

Three numbers frame it. PubMed indexes 379 records authored by Khavinson VKh, and 283 of them, about three quarters, are Russian-language. Searching epitalon and epithalon together returns 142 records, of which 52 do not carry Khavinson as an author. And ClinicalTrials.gov lists no registered studies at all for epitalon or for thymalin. So the class has a real literature and it is not small. What it does not have is separate groups asking the same question and arriving at the same answer, which is what usually turns a literature into evidence. The 266-person mortality paper is indexed as a randomised controlled trial, but it reads as a narrative summary from the institute that developed the compounds, and we could not find a repeat of that mortality figure by any group outside it.^{[11, 12, 13, 14, 15, 16]}

What has been checked outside the group

Some of it has been. In 2025 a team at Brunel University London reported that epitalon lengthened telomeres in human cell lines, working via hTERT and telomerase in normal cells and via the alternative-lengthening pathway in cancer cells; the journal published a correction to that paper later the same year. A Polish group published a review of the epitalon literature in an international journal the same year, which is the kind of outside scrutiny the class had largely gone without. So the mechanism now has independent cell-culture support behind it, while the human outcome claims still have none.^{[17, 18, 19]}

What the evidence does not show

No bioregulator peptide has an independently replicated human outcome behind it. Nothing in this literature establishes that any of them changes how long a person lives or how a particular organ behaves over time. The mechanism work, short peptides entering the nucleus and binding DNA, is real laboratory observation, but the gap between a mechanism and an outcome is where most of the selling happens. The class is widely marketed as anti-aging, and that framing traces to vendors and to the developing group's own review titles rather than to an independent human trial. Safety is unsettled for the same reason: the human record is small and largely untranslated, so the side-effect profile of these compounds is not characterised. Material bought online also carries the usual research-chemical risks of purity, endotoxin and mislabelling.^[5]

Regulatory status and sourcing

In the United States, bioregulator peptides are not approved by the FDA for any human use, and what is on sale is sold for laboratory research only. Some of the Russian preparations, Thymalin and Cortexin among them, are described in Russian-language papers as being in clinical use there, but we could not confirm their regulatory standing from a primary source, so we do not repeat it as fact. That leaves sourcing as the reader's real problem. There is no pharmacopoeial standard to hold a vendor to, and for the extract family in particular there is no way to tell from a label what is in the bottle. Anyone buying is buying on the vendor's word plus whatever third-party testing they publish.

References & sources

1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID 34834147.
2. Khavinson VK. Tissue-specific effects of peptides. Bull Exp Biol Med. 2001;132(2):807-8. Names Cortagen, Epithalon, Livagen and Vilon as synthetic peptides (cytogens). PMID 11713572.
3. Morozov VG, Khavinson VKh. [Role of cellular mediators (cytomedins) in regulating genetic activity]. Izv Akad Nauk SSSR Biol. 1985;(4):581-7. Russian-language. PMID 4056207.
4. Iakovlev GM, Morozov VG, Khavinson VKh. [Modern concepts of cytomedins and the problems of bioregulating therapy]. Voen Med Zh. 1987;(6):37-40. Russian-language review in the Soviet military medical journal. PMID 3310391.
5. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-49. Affiliation: St Petersburg Institute of Bioregulation and Gerontology. PMID 19830585.
6. PubMed search for "cytomedins", the indexed literature on the organ-extract family. 56 records at time of writing.
7. Anisimov VN, Loktionov AS, Khavinson VK, Morozov VG. Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female mice of different age. Mech Ageing Dev. 1989;49(3):245-57. PMID 2682058.
8. Khavinson VK, Izmaylov DM, Obukhova LK, Malinin VV. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000;120(1-3):141-9. PMID 11087911.
9. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. PMID 12937682.
10. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. 266 participants followed 6-8 years. PMID 14523363.
11. PubMed author search "Khavinson VKh". 379 indexed records at time of writing.
12. The same PubMed search filtered to Russian-language records. 283 of the 379 at time of writing.
13. PubMed search "epitalon OR epithalon". 142 indexed records at time of writing.
14. The same PubMed search excluding Khavinson as an author. 52 records at time of writing.
15. ClinicalTrials.gov search for "epitalon". No registered studies.
16. ClinicalTrials.gov search for "thymalin". No registered studies.
17. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. Brunel University London. PMID 40908429.
18. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;27(1):1. PMID 41240216.
19. Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. PMID 40141333.